China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from the US Food and Drug Administration (FDA) to initiate a clinical study assessing its HDM1005 in patients with obstructive sleep apnea (OSA) who are overweight or obese.
HDM1005: A Dual GLP-1 and GIP Receptor Agonist
HDM1005 is classified as a Category 1 chemical drug and is fundamentally a long-acting dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. Preclinical studies have demonstrated that HDM1005 can activate GLP-1 and GIP receptors, which in turn promote the production of cyclic adenosine monophosphate (cAMP), increase insulin secretion, suppress appetite, delay gastric emptying, and improve fat metabolism.
Potential Therapeutic Effects and Safety Profile
The drug has shown potential hypoglycemic, weight loss, and metabolic effects that could significantly improve metabolic health and sleep disorders. Moreover, existing data indicates that HDM1005 possesses good druggability and safety, making it a promising candidate for the treatment of OSA in patients with obesity or overweight conditions.-Fineline Info & Tech
